MAYO CLINIC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1889-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mayoclinic.org
Patient Outcomes After Hepatic Artery Infusion Pump Placement
Completed
- Conditions
- Colorectal CancerColorectal Liver Metastases
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT05468593
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Phase 2
Recruiting
- Conditions
- High Grade Astrocytic TumorRecurrent Glioblastoma, IDH-WildtypeRecurrent Gliosarcoma
- Interventions
- Procedure: Biospecimen CollectionBiological: Efineptakin alfaBiological: PembrolizumabProcedure: Biopsy
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 44
- Registration Number
- NCT05465954
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bringing Life to Those Near Death
Not Applicable
- Conditions
- Palliative Care
- Interventions
- Behavioral: Virtual Reality
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT05466123
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Phase 2
Recruiting
- Conditions
- Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaStage IV Fallopian Tube Cancer AJCC V8Stage IV Ovarian Cancer AJCC V8Stage IV Primary Peritoneal Cancer AJCC V8
- Interventions
- Procedure: BiopsyDrug: Pegylated SN-38 Conjugate PLX038Procedure: Computed TomographyProcedure: Biospecimen Collection
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 43
- Registration Number
- NCT05465941
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
CREST-2 Long-term Observational Extension Study
- Conditions
- Stenoses, Carotid
- Interventions
- Procedure: FDA-approved carotid stentsProcedure: Carotid EndarterectomyOther: Intensive Medical Management
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 2480
- Registration Number
- NCT05465122
- Locations
- 🇺🇸
USC/Keck Medical Center, Los Angeles, California, United States
🇺🇸VA Medical Center, Baltimore, Maryland, United States
🇺🇸Miami Cardiac and Vascular Institute, Miami, Florida, United States
Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
Phase 1
Terminated
- Conditions
- Skin Aging
- Interventions
- Biological: Human platelet extract (cosmetic product)Other: Vanicream Gentle Facial CleanserOther: EltaMD UV Daily Broad-Spectrum SPF 40Other: EltaMD PM Therapy Facial MoisturizerOther: Vanicream Lite Lotion
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 56
- Registration Number
- NCT05457491
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
Phase 1
Recruiting
- Conditions
- Kidney Transplant
- Interventions
- Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT05456243
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Performance and Accuracy of an AI Enhanced Smart Watch Single Lead ECG
Completed
- Conditions
- Healthy
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1000
- Registration Number
- NCT05450809
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
Phase 2
Completed
- Conditions
- Breast AdenocarcinomaInvasive Breast CarcinomaResectable Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionDrug: Letrozole
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 21
- Registration Number
- NCT05447910
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities
Not Applicable
Recruiting
- Conditions
- Colorectal Carcinoma
- Interventions
- Other: Educational InterventionOther: Fecal Immunochemical TestBehavioral: Patient NavigationOther: Questionnaire Administration
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 450
- Registration Number
- NCT05447923
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath